Oncternal Therapeutics Inc. buy Brookline Capital Management
Start price
11.03.23
/
50%
€0.70
Target price
11.03.24
-
Performance (%)
-62.03%
End price
12.03.24
-
Summary
This prediction is currently being closed. The BUY prediction by Brookline_Capital_Ma for Oncternal Therapeutics Inc. is performing very badly with a performance of -62.03%. Brookline_Capital_Ma has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Oncternal Therapeutics Inc. | - | - | - | - |
| iShares Core DAX® | -1,66 % | -10,87 % | -0,72 % | 41,87 % |
| iShares Nasdaq 100 | -3,77 % | -5,15 % | 13,41 % | 70,29 % |
| iShares Nikkei 225® | -2,80 % | -11,30 % | 25,46 % | 45,96 % |
| iShares S&P 500 | -2,30 % | -4,80 % | 8,94 % | 54,18 % |
Comments by Brookline_Capital_Ma for this prediction
In the thread Oncternal Therapeutics Inc. diskutieren
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) had its "buy" rating re-affirmed by analysts at Brookline Capital Management.
Ratings data for ONCT provided by MarketBeat
In the thread Trading Oncternal Therapeutics Inc.
Die von Brookline_Capital_Ma gewählte maximale Laufzeit wurde überschritten
Stopped prediction by Brookline_Capital_Ma for Oncternal Therapeutics Inc.
Oncternal Therapeutics Inc.
Start price
Target price
Perf. (%)
€0.31
04.12.23
04.12.23
€1.85
04.12.24
04.12.24
3.23%
05.12.24
05.12.24
